130 related articles for article (PubMed ID: 31538980)
21. [Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Fujii K; Nakashima K; Ohno T; Anai H
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1835-7. PubMed ID: 9382545
[TBL] [Abstract][Full Text] [Related]
22. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Grem JL; Quinn M; Ismail AS; Takimoto CH; Lush R; Liewehr DJ; Steinberg SM; Balis FM; Chen AP; Monahan BP; Harold N; Corse W; Pang J; Murphy RF; Allegra CJ; Hamilton JM
Cancer Chemother Pharmacol; 2001; 47(2):117-25. PubMed ID: 11269737
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion.
Cremona F; Izzo F; Ruffolo F; Palaia R; Parisi V
J Chemother; 1997 Apr; 9(2):140-1. PubMed ID: 9176762
[No Abstract] [Full Text] [Related]
25. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Saif MW
Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
[TBL] [Abstract][Full Text] [Related]
27. Acute encephalopathy attributed to 5-FU.
Langer CJ; Hageboutros A; Kloth DD; Roby D; Shaer AH
Pharmacotherapy; 1996; 16(2):311-3. PubMed ID: 8820478
[TBL] [Abstract][Full Text] [Related]
28. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Liaw CC; Wang HM; Wang CH; Yang TS; Chen JS; Chang HK; Lin YC; Liaw SJ; Yeh CT
Anticancer Drugs; 1999 Mar; 10(3):275-81. PubMed ID: 10327032
[TBL] [Abstract][Full Text] [Related]
29. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
30. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
[TBL] [Abstract][Full Text] [Related]
31. Toxicity of 5-fluorouracil.
Macdonald JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):33-4. PubMed ID: 10442356
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
33. Symptomatic 5-fluorouracil-induced sinus bradycardia.
Lee AD; McKay MJ
Intern Med J; 2011 Jul; 41(7):566-70. PubMed ID: 21762335
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
; Piedbois P; Rougier P; Buyse M; Pignon J; Ryan L; Hansen R; Zee B; Weinerman B; Pater J; Leichman C; Macdonald J; Benedetti J; Lokich J; Fryer J; Brufman G; Isacson R; Laplanche A; Levy E
J Clin Oncol; 1998 Jan; 16(1):301-8. PubMed ID: 9440757
[TBL] [Abstract][Full Text] [Related]
35. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
Shaib W; Lee V; Saif MW
In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
[TBL] [Abstract][Full Text] [Related]
36. Which 5-fluorouracil regimen?--the great debate.
Vincent M; Labianca R; Harper P
Anticancer Drugs; 1999 Apr; 10(4):337-54. PubMed ID: 10378668
[TBL] [Abstract][Full Text] [Related]
37. Images in clinical medicine. Serpentine supravenous hyperpigmentation.
Chan CC; Lin SJ
N Engl J Med; 2010 Jul; 363(5):e8. PubMed ID: 20830826
[No Abstract] [Full Text] [Related]
38. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Glimelius B; Jakobsen A; Graf W; Berglund A; Gadeberg C; Hansen P; Kjaer M; Brunsgaard N; Sandberg E; Lindberg B; Sellström H; Lorentz T; Påhlman L; Gustavsson B
Eur J Cancer; 1998 Apr; 34(5):674-8. PubMed ID: 9713273
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
Patel M; Ardalan K; Hochman I; Tian EM; Ardalan B
Anticancer Res; 2003; 23(1A):447-52. PubMed ID: 12680247
[TBL] [Abstract][Full Text] [Related]
40. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Streit M; Jaehde U; Stremetzne S; Ridwelski K; Kerz H; Strohbach F; Hohenberger P; Zwiebel FM; Hebart H; Böthig R; Kairies M; Zillig D; Schuchmann S; Warnecke S; Thiel E; Kreuser ED
Ann Oncol; 1997 Nov; 8(11):163-5. PubMed ID: 9426339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
